Peripheral Artery Disease: Revascularization vs Medical Therapy and VOYAGER PAD Data
Medical Management: The Foundation of PAD Care
Guideline-directed medical therapy (GDMT) for PAD includes high-intensity statin therapy (target LDL <70 mg/dL, ideally <55 mg/dL per 2024 guidelines), antiplatelet therapy, blood pressure control (<130/80 mmHg), diabetes optimization, smoking cessation, and supervised exercise therapy. The CLEVER trial demonstrated that supervised exercise improved peak walking time by 5.8 minutes at 6 months versus 3.7 minutes for stenting and 1.2 minutes for optimal medical therapy alone in aortoiliac PAD, though stenting produced more rapid functional improvement.
Intermittent Claudication: When to Intervene
For lifestyle-limiting claudication refractory to 3+ months of supervised exercise and GDMT, revascularization is reasonable. The ACC/AHA guidelines recommend endovascular-first approaches for most aortoiliac disease (TransAtlantic Inter-Society Consensus TASC A-C lesions) and infrainguinal lesions under 25 cm. For femoropopliteal disease, drug-coated balloons (DCB) and drug-eluting stents (DES) have improved patency: the IN.PACT Admiral trial showed DCB primary patency of 83% versus 60% for uncoated balloon at 12 months. Cilostazol 100 mg BID (NNT 6 for symptom improvement) should be trialed in claudicants before invasive intervention if not contraindicated by heart failure.
Chronic Limb-Threatening Ischemia: BEST-CLI Results
The BEST-CLI trial (1,830 CLTI patients) compared surgical bypass to endovascular intervention. In patients with adequate great saphenous vein (GSV) conduit, bypass was superior with a 32% reduction in the composite of major adverse limb events, including amputation and reintervention (HR 0.68, 95% CI 0.59-0.79). In patients without adequate GSV, outcomes were similar between approaches (HR 0.79, 95% CI 0.58-1.06). This supports the primacy of surgical bypass with autogenous conduit for CLTI when vein quality is adequate.
Sponsored
Antithrombotic Therapy: COMPASS and VOYAGER PAD
The COMPASS trial demonstrated that rivaroxaban 2.5 mg BID plus aspirin reduced MACE and major adverse limb events (MALE) by 28% compared to aspirin alone in stable PAD (HR 0.72, 95% CI 0.57-0.90), with a 46% reduction in major amputation. The VOYAGER PAD trial extended this to post-revascularization patients, showing rivaroxaban 2.5 mg BID plus aspirin reduced the composite of acute limb ischemia, major amputation, MI, ischemic stroke, or CV death by 15% (HR 0.85, 95% CI 0.76-0.96) without significantly increased ISTH major bleeding (TIMI major bleeding 2% both arms). Dual-pathway inhibition is now recommended for symptomatic PAD patients at high limb event risk who are not at high bleeding risk.
Structured Exercise Programs
Supervised exercise therapy (SET) remains underutilized despite strong evidence: Medicare approved coverage for SET in PAD beginning in 2017. Programs typically involve 36 sessions over 12 weeks of treadmill walking to moderate-to-severe claudication, resting, and repeating for 30-50 minutes. The ERASE trial demonstrated SET improved 6-minute walk distance by 53 meters versus usual care (p<0.001). Home-based exercise programs with wearable activity monitors are emerging as alternatives, with the GOALS trial showing similar improvement in walking distance with structured home exercise versus supervised programs at 12 months.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.